CAPRICOR THERAPEUTICS, INC.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2025-06-30; filed 2025-08-11.
0001558370-25-011084
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2025-09-30; filed 2025-11-10.
0001104659-25-109298
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 4 previous paragraphs and 4 current paragraphs.
2 unchanged; 2 reworded; 0 added; 0 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Reworded paragraphs (2)
Previous wording
We will incur costs in connection with defending securities class action litigation and derivative claims recently initiated by certain of our stockholders.
Current wording
We will incur costs in connection with defending securities class action litigation, the derivative claims and the Section 220 Demand for Inspection recently initiated by certain of our stockholders.
Previous wording
As noted in our Form 10-K for the year ended December 31, 2024, we may become subject to securities class action litigation or litigation initiated by individual stockholders. This risk is especially relevant due to our dependence on positive clinical trial outcomes and regulatory approvals. As noted in this Form 10-Q, we have now received notice of a putative class action and of a derivative action from certain of our stockholders. Responding to these claims will be costly and time-consuming to us, and may cause management to have to divert attention and resources from the pursuit of our business strategies, any of which could harm our business and result in a decline in the market price of our common stock.
Current wording
As noted in our Form 10-K for the year ended December 31, 2024, we may become subject to securities class action litigation or litigation initiated by individual stockholders. This risk is especially relevant due to our dependence on positive clinical trial outcomes and regulatory approvals. As noted in this Form 10-Q, we have now received notice of a putative class action, a derivative action and a Section 220 Demand for Inspection from certain of our stockholders. Responding to these claims will be costly and time-consuming to us, and may cause management to have to divert attention and resources from the pursuit of our business strategies, any of which could harm our business and result in a decline in the market price of our common stock.